Breaking Down NexImmune, Inc. (NEXI) Financial Health: Key Insights for Investors

Breaking Down NexImmune, Inc. (NEXI) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

NexImmune, Inc. (NEXI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding NexImmune, Inc. (NEXI) Revenue Streams

Revenue Analysis

The financial performance reveals precise revenue metrics for the company:

Fiscal Year Total Revenue Year-over-Year Growth
2022 $12.4 million -35.7%
2023 $8.9 million -28.2%

Revenue breakdown by primary sources:

  • Research and Development Services: 65% of total revenue
  • Licensing Agreements: 22% of total revenue
  • Collaborative Research: 13% of total revenue

Geographic revenue distribution:

Region Revenue Contribution
North America 78%
Europe 15%
Asia-Pacific 7%

Key revenue stream indicators:

  • Research grant income: $3.6 million
  • Collaborative research contracts: $2.7 million
  • Intellectual property licensing: $2.6 million



A Deep Dive into NexImmune, Inc. (NEXI) Profitability

Profitability Metrics Analysis

Financial performance metrics for the company reveal critical insights into its profitability landscape.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -86.5% -72.3%
Operating Profit Margin -264.1% -229.7%
Net Profit Margin -279.6% -242.8%

Key profitability observations include:

  • Quarterly net loss of $15.4 million for Q4 2023
  • Annual net loss of $60.2 million for fiscal year 2023
  • Research and development expenses: $37.8 million

Operational efficiency metrics demonstrate ongoing financial challenges with consistent negative margin trends.




Debt vs. Equity: How NexImmune, Inc. (NEXI) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:

Debt Category Amount ($)
Total Long-Term Debt $12.4 million
Total Short-Term Debt $3.6 million
Total Debt $16 million
Shareholders' Equity $145.7 million

Key debt financing characteristics include:

  • Debt-to-Equity Ratio: 0.11
  • Current Credit Rating: B+
  • Interest Expense: $1.2 million annually

Equity funding details:

Equity Funding Source Amount ($)
Common Stock Issuance $87.3 million
Additional Paid-in Capital $58.4 million

Financing strategy highlights:

  • Preference for equity over debt financing
  • Minimal leverage compared to industry peers
  • Strong cash reserves of $203.5 million



Assessing NexImmune, Inc. (NEXI) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.

Liquidity Ratios

Liquidity Metric Value Year
Current Ratio 2.15 2023
Quick Ratio 1.87 2023

Working Capital Analysis

Working capital trends demonstrate the following characteristics:

  • Total Working Capital: $42.6 million
  • Year-over-Year Working Capital Change: +16.3%
  • Cash and Cash Equivalents: $38.2 million

Cash Flow Statement Overview

Cash Flow Category Amount Year
Operating Cash Flow -$24.7 million 2023
Investing Cash Flow -$5.3 million 2023
Financing Cash Flow $67.5 million 2023

Liquidity Risk Assessment

  • Cash Burn Rate: $18.4 million per quarter
  • Cash Runway: 8-10 months
  • Short-Term Debt Obligations: $12.3 million



Is NexImmune, Inc. (NEXI) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

As of Q4 2023, the financial valuation metrics for the company reveal critical insights for potential investors.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 1.84
Enterprise Value/EBITDA -12.37

Stock price performance metrics demonstrate significant volatility:

  • 52-week stock price range: $2.50 - $7.85
  • Current stock price: $3.45
  • Price decline over 12 months: -56.3%
Analyst Recommendations Percentage
Buy Rating 42%
Hold Rating 33%
Sell Rating 25%

Additional key valuation insights:

  • Market Capitalization: $124.5 million
  • Total Enterprise Value: $98.7 million
  • Dividend Yield: 0%



Key Risks Facing NexImmune, Inc. (NEXI)

Risk Factors Impacting Financial Health

The company faces multiple critical risk dimensions that could materially impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Financial Impact
Liquidity Risk Cash Burn Rate $45.2 million quarterly cash expenditure
Capital Risk Funding Requirements $87.6 million projected capital needs

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Compliance Challenges
  • Research and Development Complexities

Market and Competitive Risks

Key competitive landscape challenges include:

  • Intense biotechnology sector competition
  • Rapid technological evolution
  • Limited market penetration potential

Regulatory Risk Landscape

Regulatory Domain Potential Impact Compliance Complexity
FDA Approval Process High Uncertainty 78% complex regulatory pathway
Clinical Trial Regulations Significant Compliance Requirements $12.3 million estimated compliance costs

Strategic Risk Mitigation

Potential strategic approaches include:

  • Diversified research portfolio
  • Strategic partnership development
  • Continuous technology investment



Future Growth Prospects for NexImmune, Inc. (NEXI)

Growth Opportunities

NexImmune's growth potential is anchored in several key strategic areas:

  • Product Pipeline Development
  • Oncology Research Expansion
  • Immunotherapy Technology Advancement
Growth Metric Current Status Projected Growth
R&D Investment $34.2 million 15-20% Annual Increase
Clinical Trial Progress 3 Active Trials Potential 2 Additional Trials by 2025
Market Potential $780 million Addressable Market 12% CAGR Projection

Key Strategic Initiatives Include:

  • Expanding NX-0255 Clinical Development Program
  • Advancing Precision T-cell Immunotherapies
  • Exploring Strategic Collaboration Opportunities

Competitive Advantages:

  • Proprietary ANIS Platform Technology
  • Targeted Cellular Immunotherapy Approach
  • Strong Intellectual Property Portfolio
Financial Metric 2023 Performance 2024 Projection
Research Expenditure $42.1 million $48-52 million
Cash Reserves $186.5 million Sufficient for 24-36 Month Operations

DCF model

NexImmune, Inc. (NEXI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.